Company intelligence / Profile preview

enGene

Ownership: Public · ENGN
Development stage: Phase 2

Overview

enGene’s lead candidate, EG‑70 (detalimogene voraplasmid), a non‑viral immunotherapy delivered via the proprietary DDX platform, is in a pivotal Phase 1/2 registrational study (“LEGEND”) targeting BCG-unresponsive NMIBC with carcinoma in situ. Interim data are expected mid‑2024. The therapy aims to generate a local immune response against tumors while offering ease of administration and potentially improved safety compared to viral-based gene therapies. Early results suggest promising therapeutic activity and safety profile.

Therapeutic areas: OncologyImmunology
Modalities: Non-viral gene therapies (DNA plasmid-based)polymeric nanoparticles
Industry: Biotech

Drug pipeline

2 assets

detalimogene voraplasmid

1 more asset in the full pipeline.

Request access →

Partnerships

Not specifically listed; no major pharma partnerships disclosed as of latest updates.

Financials

Market cap: $128.6M
Total revenue: $0
Enterprise value: $-129.8M

Beyond the preview

Go deeper on enGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on enGene.

Explore the full profile